Japanese Journal of Oncology and Clinical Research ©2023 The Authors. Published by the JScholar under the terms of the Crea-tive Com- mons Attribution License http://creativecommons.org/licenses/by/3.0/, which per- mits unrestricted use, provided the original author and source are credited. JScholar Publishers JJ Oncol Clin Res 2023 | Vol 4: 202 Research Article Open Access Melatonin: The Nighttime Hormone's Role in Cancer Control and Immunity En- hancement A Tavartkiladze 1,2,* , G Simonia 1,2 , D Kasradze 1,3 , P Revazishvili 1,2 , D Egiazaroiv 1 , Nana Okrostsvaridze 2 , R Kut- sishvili 1,2 , M Maisuradze 1 , I Andronikashvili 1,2 , T Potskoraia 1 , T Japaridze 1 and G Dundua 1 1 Institute for Personalized Medicine, Georgia 2 Tbilisi State Medical University, Georgia 3 David Tvildiani Medical University, Georgia * Corresponding Author: A Tavartkiladze, Institute for Personalized Medicine, Georgia, Tel: +995 577 09 09 77, E-mail: alexandre.tavartkiladze@gmail.com Received Date: October 25, 2023 Accepted Date: November 25, 2023 Published Date: November 27, 2023 Citation: A Tavartkiladze, G Simonia, D Kasradze, P Revazishvili, D Egiazaroiv et al. (2023) Melatonin: The Nighttime Hor- mone's Role in Cancer Control and Immunity Enhancement. JJ Oncol Clin Res 4: 1-13 Abstract Introduction and Aim: Recent research has expanded our understanding of melatonin, a hormone secreted by the pineal gland, particularly in its complex role in oncological pathologies. This study aimed to explore melatonin's multifaceted role in cancer progression and its potential to enhance the efficacy of cytostatic agents. Methodology: In a controlled experimental setting, 45 cancer patients at various stages, including stage four and grade G3 cancers, were administered oral melatonin. Doses ranged from 10 mg to 60 mg daily over an 11-month period. A control group consisted of 20 healthy physicians. Parameters measured included cancer regression indicators and 24-hour urinary melatonin sulfate excretion. Results: The administration of melatonin resulted in significant cancer regression in patients, as evidenced by increased ex- cretion of melatonin sulfate. This finding was correlated with improvements in clinical oncological outcomes. Discussion: Melatonin exhibits a range of biological properties, including antioxidant, autocoid, paracoid, and hormonal ac- tivities, as well as anti-inflammatory and anti-apoptotic effects. It plays a crucial role in regulating various physiological pro- cesses and has shown promising results in modulating immune responses and influencing cancer cell apoptosis. In particu- lar, its effects on decreasing metastasis in breast cancer and modulating gene expression for DNA repair highlight its poten- tial as a therapeutic agent in cancer treatment. The study's findings contribute to the understanding of melatonin's inhibito- ry effects on cancer cell proliferation and its role in enhancing the response to conventional cancer therapies.